Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder

2020 ◽  
Vol 5 (1) ◽  
pp. 45-55 ◽  
Author(s):  
Rachael L. Sumner ◽  
Rebecca McMillan ◽  
Meg J. Spriggs ◽  
Doug Campbell ◽  
Gemma Malpas ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Evoked Potential ◽  
Long Term Potentiation ◽  
Major Depressive ◽  
Sensory Evoked Potential ◽  
Term Potentiation ◽  
Sensory Evoked

The Long-Term Effects of Mindfulness-Based Cognitive Therapy as a Relapse Prevention Treatment for Major Depressive Disorder

2010 ◽  
Vol 38 (5) ◽  
pp. 561-576 ◽  
Author(s):  
Kate L. Mathew ◽  
Hayley S. Whitford ◽  
Maura A. Kenny ◽  
Linley A. Denson
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cognitive Therapy ◽  
Relapse Prevention ◽  
Mindfulness Practice ◽  
Long Term Effects ◽  
Major Depressive ◽  
Strong Negative Correlation ◽  
Group 3

Background: Mindfulness-based Cognitive Therapy (MBCT) is a relapse prevention treatment for major depressive disorder. Method: An observational clinical audit of 39 participants explored the long-term effects of MBCT using standardized measures of depression (BDI-II), rumination (RSS), and mindfulness (MAAS). Results: MBCT was associated with statistically significant reductions in depression from pre to post treatment. Gains were maintained over time (Group 1, 1–12 months, p = .002; Group 2, 13–24 months, p = .001; Group 3, 25–34 months, p = .04). Depression scores in Group 3 did begin to worsen, yet were still within the mild range of the BDI-II. Treatment variables such as attendance at “booster” sessions and ongoing mindfulness practice correlated with better depression outcomes (p = .003 and p = .03 respectively). There was a strong negative correlation between rumination and mindful attention (p < .001), consistent with a proposed mechanism of metacognition in the efficacy of MBCT. Conclusion: It is suggested that ongoing MBCT skills and practice may be important for relapse prevention over the longer term. Larger randomized studies of the mechanisms of MBCT with longer follow-up periods are recommended.

Short-term and long-term effects of major depressive disorder subtypes on obesity markers and impact of sex on these associations

2021 ◽  
Author(s):  
Clémentine Ottino ◽  
Marie-Pierre F Strippoli ◽  
Mehdi Gholam ◽  
Aurélie M Lasserre ◽  
Caroline L Vandeleur ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Long Term Effects ◽  
Short Term ◽  
Major Depressive

scholarly journals Perceived Impeding Factors for Return-to-Work after Long-Term Sickness Absence Due to Major Depressive Disorder: A Concept Mapping Approach

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e85038 ◽  
Author(s):  
Gabe de Vries ◽  
Hiske L. Hees ◽  
Maarten W. J. Koeter ◽  
Suzanne E. Lagerveld ◽  
Aart H. Schene
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Return To Work ◽  
Concept Mapping ◽  
Sickness Absence ◽  
Major Depressive ◽  
Mapping Approach

T161. Long-Term Potentiation-Like Visual Evoked Potential Plasticity in a Large Sample of Healthy Volunteers: Effect Sizes and Response Rates

2018 ◽  
Vol 83 (9) ◽  
pp. S190-S191
Author(s):  
Mathias Valstad ◽  
Torgeir Moberget ◽  
Lars T. Westlye ◽  
Daniël T.H. Roelfs ◽  
Knut Skaug ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
Response Rates ◽  
Long Term Potentiation ◽  
Effect Sizes ◽  
Large Sample ◽  
Term Potentiation ◽  
Visual Evoked

scholarly journals 50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results

CNS Spectrums ◽  
2019 ◽  
Vol 24 (1) ◽  
pp. 203-204 ◽  
Author(s):  
Michael Thase ◽  
Arielle D. Stanford ◽  
Asli Memisoglu ◽  
William Martin ◽  
Amy Claxton ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Safety Profile ◽  
Rating Scale ◽  
Remission Rate ◽  
Term Treatment ◽  
Adjunctive Treatment ◽  
Major Depressive ◽  
Long Term Treatment

AbstractIntroductionBuprenorphine/samidorphan (BUP/SAM), a combination of BUP (a µ-opioid receptor partial agonist and κ-antagonist) and SAM (a sublingually bioavailable µ-opioid antagonist), is an investigational opioid system modulator for depression. BUP/SAM has shown efficacy versus placebo as an adjunctive treatment for major depressive disorder (MDD) and a consistent safety profile in previously reported, placebo-controlled clinical studies.1,2Study Objective(s)1. To characterize the safety profile following long-term treatment with BUP/SAM2. To explore depression symptoms and remission rates in patients with MDD following long-term treatment with BUP/SAMMethodsFORWARD-2 (Clinicaltrials.gov ID: NCT02141399) enrolled patients who had participated in 1 of 4 controlled studies as well as de novo patients. All patients had a confirmed diagnosis of MDD, had a history of inadequate response to standard antidepressant therapies (ADTs), and had been treated with an adequate dose of an established ADT for ≥8weeks before BUP/SAM initiation. ADT dosage could be titrated, but the ADT could not be changed. During the study, patients received open-label, sublingual BUP/SAM 2mg/2mg as adjunctive treatment for up to 52weeks. Safety (primary objective) was assessed via adverse events (AEs), vital signs, laboratory analytes, and electrocardiography. Suicidal ideation or behavior (SIB) was evaluated by the Columbia Suicide Severity Rating Scale. Abuse potential, dependence, and withdrawal were assessed by AEs and the Clinical Opiate Withdrawal Scale. Exploratory efficacy endpoints included mean Montgomery–Åsberg Depression Rating Scale (MADRS) scores and remission rate (MADRS ≤10).ResultsOf 1454 total patients, 49% completed the 52-week study, 11% discontinued due to an AE, and 40% discontinued because of other reasons as of the interim data cutoff date (April 30, 2017). Most AEs were of mild/moderate severity. Serious AEs were reported in 3.2% of patients. AEs occurring in ≥10% of patients were nausea, headache, constipation, dizziness, and somnolence. There was no evidence of increased risk of SIB with BUP/SAM. Incidence of euphoria-related events was low (1.2%). After abrupt discontinuation of BUP/SAM, there was little evidence of withdrawal. BUP/SAM was not associated with meaningful changes in laboratory or metabolic parameters or in bodyweight. The mean MADRS score decreased from 22.9 (±9.7) at baseline to 9.8 (±8.8) after 52weeks. The remission rate at 52weeks was 52.5%.ConclusionsLong-term treatment with BUP/SAM did not reveal any new safety findings and confirmed that the risk of abuse and dependence with BUP/SAM was low. BUP/SAM maintained an antidepressant effect for up to 52weeks of treatment in patients with MDD.Funding Acknowledgements: Alkermes, Inc.

Sign in / Sign up

Export Citation Format

Share Document